Insider Monkey
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug
📊
AI Sentiment
Positive
6/10
- Home
- MDGL
as of 12-03-2025 2:05pm EST
$581.20
+$8.05
+1.40%
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Chart Type:
Time Range:
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 9.6B | IPO Year: | N/A |
| Target Price: | $543.33 | AVG Volume (30 days): | 415.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $265.00 - $605.00 | Next Earning Date: | 11-04-2025 |
| Revenue: | $740,640,000 | Revenue Growth: | 864.21% |
| Revenue Growth (this year): | 395.75% | Revenue Growth (next year): | 65.73% |
AI-Powered MDGL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 80.54%
80.54%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
Levy Richard S
Sell
Director
MDGL Nov 13, 2025
Avg Cost/Share
$522.34
Shares
8,500
Total Value
$4,428,197.57
Owned After
21,197
BATE KENNETH
Sell
Director
MDGL Nov 5, 2025
Avg Cost/Share
$485.61
Shares
16,575
Total Value
$8,027,354.15
Owned After
17,439
Sibold William John
Sell
President and CEO
MDGL Sep 9, 2025
Avg Cost/Share
$445.63
Shares
7,279
Total Value
$3,243,740.77
Owned After
102,474
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Levy Richard S | MDGL | Director | Nov 13, 2025 | Sell | $522.34 | 8,500 | $4,428,197.57 | 21,197 | |
| BATE KENNETH | MDGL | Director | Nov 5, 2025 | Sell | $485.61 | 16,575 | $8,027,354.15 | 17,439 | |
| Sibold William John | MDGL | President and CEO | Sep 9, 2025 | Sell | $445.63 | 7,279 | $3,243,740.77 | 102,474 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Simply Wall St.
Is Madrigal Pharmaceuticals Still Attractively Priced After 42.6% Surge on R&D Progress?
📈
AI Sentiment
Highly Positive
8/10
Motley Fool
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
📊
AI Sentiment
Positive
7/10
Motley Fool
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year
âž–
AI Sentiment
Neutral
5/10
Compare MDGL vs Leading Stocks
See how MDGL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.